Beovu · DIN 02496976 · 6 mg/0.05 mL · injection, 0.05 mL pre-filled syringe (preservative-free)
Limited Use, Reason for Use code 620, 648 requiredMarketed · checked November 19, 2026
StatusLimited Use, Reason for Use code 620, 648 required
Write on scriptone applicable Reason for Use code, 620 or 648 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 620, 648
Reason for Use code 620
For the treatment of patients with mild-to-moderate neovascular (wet) age-related macular degeneration (AMD) in a treatment-naive eye.
Initial diagnosis should be confirmed by an appropriate diagnostic procedure and administration should be done by a qualified opthalmologist experienced in intravitreal injections.
Patients receiving concurrent administration of verteporfin PDT (Visudyne), ranibizumab (Lucentis) or aflibercept (Eylea) are not eligible for reimbursement.
Treatment should be initiated with a monthly intravitreal injection for the first 3 consecutive doses, followed by one injection every 3 months.
The interval between two doses should not be shorter than eight weeks.
Treatment with anti-VEGF agents should only be continued in patients who maintain adequate response to therapy and should be discontinued if any of the following occurs:
i. reduction in best corrected visual acuity (BCVA) in the treated eye to less than 15 letters (absolute) on two consecutive visits attributed to AMD in the absence of other pathology
ii. reduction of BCVA of 30 letters or more compared to baseline and/or best recorded level since baseline as this may indicate either poor treatment effect or adverse event or both
iii. evidence of deterioration of the lesion morphology despite treatment over three consecutive visits.
For clarity, coverage will be provided for patients responding to therapy with Lucentis or Eylea who switch to Beovu. Coverage will NOT be provided for patients who have failed to respond to Lucentis or Eylea.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 648
For the treatment of patients with clinically significant diabetic macular edema (DME) for whom laser photocoagulation is also indicated; and who have a hemoglobin A1c of less than 12 percent.
Treatment should be initiated with an intravitreal injection every 6 weeks for the first 5 consecutive doses, followed by one injection every 8 to 12 weeks. An interval of 8 weeks may be considered for those with disease activity, whereas an interval of up to 12 weeks may be considered for those without disease activity.
After the first 5 initiation doses, the interval between two doses should not be shorter than 8 weeks.
Treatment with anti-VEGF agents should only be continued in patients who maintain adequate response to therapy.
For clarity, coverage will be provided for patients responding to therapy with another anti-VEGF agent who switch to Beovu. Coverage will NOT be provided for patients who have failed to respond to another anti-VEGF agent.
Coverage limit:
LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Beovu · DIN 02496976
Manufacturer: Novartis Pharma Canada Inc.; listing date 2021-12-17
Health Canada: Marketed since 2020-05-15 · brand BEOVU · ATC S01LA06 BROLUCIZUMAB · form Solution · route Intravitreal · ingredients BROLUCIZUMAB 6 MG/0.05ML · company Novartis pharmaceuticals canada inc · schedule Prescription
Beovu: Formulary list price $1390.00 per unit (the source does not state the unit; exact figure $1390.0000). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02496976)
Source record
DIN 02496976: Beovu
Raw flags: sec12=Y, sec3=Y
Item: 523600148; group id 619; item number 1586; lccId 00349; manufacturer id NOV
Source form: Inj Sol-0.05mL Pref Syr (Preservative-Free); strength: 6mg/0.05mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1390.0000; ministry $1390.0000
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02496976
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98684
Shortage status: not checked (no credentials)